ArticleFrontiers in immunology2026
Interferon-λ-neutralizing autoantibodies and common autoimmune disease autoantibodies in pediatric acute-onset neuropsychiatric syndrome.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- High levels of nonblocking anti-interferon and anticytokine autoantibodies in individuals with mRNA vaccine-induced systemic allergic reactions.The journal of allergy and clinical immunology. Global · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
Pediatric Acute-onset Neuropsychiatric Syndrome (PANS) is characterized by sudden onset obsessive-compulsive disorder (OCD) symptoms in conjunction with other neuropsychiatric manifestations including disturbances in sleep, cognition, and behavior. Studies have revealed high rates of autoimmune and inflammatory markers-as well as comorbid rheumatologic disease-in patients with PANS. While published studies have suggested autoantibodies are common in PANS patients, the molecular targets of these autoantibodies (AAbs) remain poorly characterized. Here, we profile the AAbs in 224 plasma samples taken from 166 PANS patients during periods of active disease, or flares, compared to 83 pediatric healthy controls using custom Luminex microbead panels conjugated with highly curated antigens from common autoimmune diseases as well as cytokines and chemokines. We find that PANS patients exhibit increased prevalence of AAbs against autoantigens known to be targeted in scleroderma and GI/endocrine autoimmune conditions. Furthermore, a subset of PANS patients exhibited AAbs against IFN-λ, an important line of defense against infections at anatomic barriers. Among the 11 tested PANS plasma samples with IFN-λ-binding AAbs, 9 showed detectable inhibition of IFN-λ signaling, and 4 met our predefined stringent threshold for IFN-λ-neutralizing activity, while no tested HC samples met this neutralization threshold. These findings support a link between autoimmunity and PANS, and may provide insight into a potential disease mechanism mediated by immune deficits at barrier surfaces in a subset of patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.